PRO-DEX, INC. — Form 10-Q Summary
Business context and period. This unaudited report covers the three months ended September 30, 2011, the first quarter of Pro-Dex’s fiscal 2012, and compares results with the quarter ended September 30, 2010. The company designs and manufactures products for medical, aerospace, military, research, and industrial applications. Medical products generated 70% of quarterly sales.
Key financial results
| Metric | Quarter ended Sep. 30, 2011 | Prior-year quarter |
|---|---|---|
| Net sales | $6.030 million | $5.829 million |
| Gross profit / margin | $2.329 million / 38% | $2.184 million / 37% |
| Operating income / margin | $457,000 / 7% | $405,000 / 7% |
| Net income | $446,000 | $342,000 |
| Diluted earnings per share | $0.14 | $0.10 |
| Operating cash flow | $349,000 | $381,000 |
Sales rose 3%; net income increased approximately 30%. Gross margin improved by about one percentage point. Selling, general and administrative expenses were $1.210 million (20% of sales), compared with $1.188 million (20%); research and development rose to $662,000 from $591,000. Interest expense fell to $10,000 from $57,000, mainly reflecting prior repayment of the Carson City mortgage.
Cash and cash equivalents were $4.907 million at September 30, versus $4.689 million at June 30, 2011. Working capital was $8.324 million; total assets were $15.315 million. Bank debt totaled $1.042 million, comprising $357,000 current and $685,000 non-current; cash net of bank debt was $3.865 million. The company had $1.422 million of available revolving credit and no revolver borrowings. It reported compliance with its bank covenants.
Operating cash flow was $349,000; investing cash outflow was $42,000 and financing cash outflow was $89,000, resulting in a $218,000 increase in cash. The cash-flow statement attributes operating cash generation principally to net income and lower receivables, partly offset by inventory and prepaid expense increases and lower payables/accruals.
Material changes and management commentary
- Fractional-horsepower motor sales increased $337,000 (52%). Medical-device sales rose $249,000 (6%), while motion-control sales declined $386,000, primarily due to lower sales to a major customer.
- At September 30, backlog was $11.2 million. Management noted that bookings may vary with product launches and customer inventory plans; the filing gives no formal earnings or revenue guidance.
- Warranty expense increased to $234,000 from $104,000, including $99,000 of changes to prior-period estimates. The warranty reserve was $713,000 at quarter-end.
- The income-tax provision was $1,000. A valuation allowance remained against deferred tax assets; unrecognized tax benefits were $285,000. Management did not expect a significant change in unrecognized benefits over the next 12 months.
Principal risks, contingencies, and unusual items
- Major-customer exposure: Two customers each represented more than 10% of quarterly sales; together they accounted for about 67%. The customer described as the largest medical-device customer generated $2.388 million, about 40% of sales. It has said it intends to develop and manufacture comparable products itself and did not plan new orders for Products A and B after fulfilling existing orders. Remaining orders at October 31 were $940,000 for Product A, scheduled through April 2012, and $1.638 million for Product B, scheduled through February 2012. The customer’s transition depends on regulatory and product-testing milestones and could be accelerated, delayed, or abandoned. Pro-Dex warned that its revenue from this customer could fall to negligible levels by fiscal year-end 2012, with a material adverse business impact. It is pursuing replacement revenue and may reduce costs, but neither outcome is assured.
- Environmental matter: The company’s $250,000 settlement with the Orange County Water District was paid in May 2011 with insurer funds, and the case was dismissed with prejudice in August. A state report identified the former Santa Ana site for screening; the agency said it would not evaluate the site in fiscal 2012. Any future implications remain uncertain.
- Management reported no material pending litigation known to it. The filing cautions that future legal liability cannot be ruled out.
- New accounting guidance on fair-value measurement and comprehensive-income presentation was under evaluation; management did not anticipate a material financial-statement impact from the fair-value guidance.
Investor verification priorities
- Track the major customer’s order amendments, remaining deliveries, product-transition milestones, and share of sales; verify whether new customers or cost actions offset any lost business.
- Assess backlog conversion and customer concentration alongside inventory growth, receivable collections, and operating cash flow.
- Monitor gross margin and warranty claims, particularly the elevated warranty expense and changes in estimates.
- Review debt amortization, available revolver capacity, and continued compliance with quarterly liquidity and annual profitability covenants.
- Follow developments, if any, regarding the former Santa Ana site and the company’s deferred-tax-asset valuation allowance.